Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 16, 2014, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $63.36 to $15,595,781.10.

Highlighted Stocks Traded by Insiders:

NovaBay Pharmaceuticals (NBY) - FREE Research Report

Stroman David W., who is SVP, Ophthalmic Product Devt. at NovaBay Pharmaceuticals, bought 10,000 shares at $0.66 on Dec. 16, 2014. Following this transaction, the SVP, Ophthalmic Product Devt. owned 23,000 shares meaning that the stake was boosted by 76.92% with the 10,000-share transaction.

The shares most recently traded at $0.65, down $0.01, or 1.54% since the insider transaction. Historical insider transactions for NovaBay Pharmaceuticals go as follows:

  • 4-Week # shares bought: 133,000
  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 133,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 133,000
  • 24-Week # shares sold: 30,000

The average volume for NovaBay Pharmaceuticals has been 145,000 shares per day over the past 30 days. NovaBay Pharmaceuticals has a market cap of $35.6 million and is part of the health care sector and drugs industry. Shares are down 46.18% year-to-date as of the close of trading on Monday.

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. Currently, there are no analysts who rate NovaBay Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBY - FREE

TheStreet Quant Ratings rates NovaBay Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full NovaBay Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

WPX Energy (WPX) - FREE Research Report

Lowrie William G, who is Director at WPX Energy, bought 5,000 shares at $10.35 on Dec. 16, 2014. Following this transaction, the Director owned 155,325 shares meaning that the stake was boosted by 3.33% with the 5,000-share transaction.

The shares most recently traded at $10.65, up $0.30, or 2.82% since the insider transaction. Historical insider transactions for WPX Energy go as follows:

  • 4-Week # shares bought: 45,000
  • 4-Week # shares sold: 11,820
  • 12-Week # shares bought: 55,000
  • 12-Week # shares sold: 11,820
  • 24-Week # shares bought: 65,000
  • 24-Week # shares sold: 11,820

The average volume for WPX Energy has been 4.1 million shares per day over the past 30 days. WPX Energy has a market cap of $2.2 billion and is part of the basic materials sector and energy industry. Shares are down 49.61% year-to-date as of the close of trading on Monday.

WPX Energy, Inc., an independent natural gas and oil exploration and production company, is engaged in the exploitation and development of unconventional properties in the United States. Currently, there are 3 analysts who rate WPX Energy a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WPX - FREE

TheStreet Quant Ratings rates WPX Energy as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. Get the full WPX Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Kratos Defense & Security Solutions (KTOS) - FREE Research Report

Demarco Eric M, who is President & CEO at Kratos Defense & Security Solutions, bought 21,575 shares at $4.63 on Dec. 16, 2014. Following this transaction, the President & CEO owned 373,275 shares meaning that the stake was boosted by 6.13% with the 21,575-share transaction.

Lund Deanna H, who is Executive VP & CFO at Kratos Defense & Security Solutions, bought 3,000 shares at $4.60 on Dec. 16, 2014. Following this transaction, the Executive VP & CFO owned 61,483 shares meaning that the stake was boosted by 5.13% with the 3,000-share transaction.

The shares most recently traded at $4.28, down $0.32, or 7.41% since the insider transaction. Historical insider transactions for Kratos Defense & Security Solutions go as follows:

  • 4-Week # shares bought: 7,500
  • 12-Week # shares bought: 7,500
  • 24-Week # shares bought: 7,500

The average volume for Kratos Defense & Security Solutions has been 503,200 shares per day over the past 30 days. Kratos Defense & Security Solutions has a market cap of $264.1 million and is part of the services sector and diversified services industry. Shares are down 43.75% year-to-date as of the close of trading on Monday.

Kratos Defense & Security Solutions, Inc. provides mission critical products, solutions, and services primarily for the United States Government. The company operates in two segments, Kratos Government Solutions, and Public Safety and Security. The company has a P/E ratio of 14.3. Currently, there are 3 analysts who rate Kratos Defense & Security Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on KTOS - FREE

TheStreet Quant Ratings rates Kratos Defense & Security Solutions as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full Kratos Defense & Security Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: Shark Tank Star Kevin O'Leary on Netflix, Amazon and Trade Worries

Video: Shark Tank Star Kevin O'Leary on Netflix, Amazon and Trade Worries

Bank of America Up 3.9% on Earnings Beat, But Analysts See Even More Gains Ahead

Bank of America Up 3.9% on Earnings Beat, But Analysts See Even More Gains Ahead

Microsoft's Growing Public Cloud Is Exciting: Morgan Stanley

Microsoft's Growing Public Cloud Is Exciting: Morgan Stanley

Here's How Shark Tank Star Kevin O'Leary Decides What Stocks to Invest In

Here's How Shark Tank Star Kevin O'Leary Decides What Stocks to Invest In

Dow Rises Slightly, Netflix Trades Higher Ahead of Earnings

Dow Rises Slightly, Netflix Trades Higher Ahead of Earnings